Also Read: Lupin to rely on Antara sales to rebuild brand: MD
"The company has received (ANDA) approval from the US Food an Drug Administration (USFDA) for amlodipine besylate tablets," Unichem Laboratories said in a filing to BSE. The product in the strengths of 2.5 mg, 5 mg and 10 mg are equivalent to Pfizer Inc's Norvasc tablets in the same strengths, it added.
"Currently there are 6 to 7 companies dominating the US market. The current market size is around USD 45-50 million," Unichem Laboratories said. The product will be commercialised from the company's Goa facility, it added.
"Amlodipine besylate tablets is a calcium channel blocker indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and non fatal cardiovascular events...," Unichem said. Shares of Unichem Laboratories today closed at Rs 166.65 per scrip on BSE, up 1.21 percent from its previous close.
On October 24, 2013, Unichem Laboratories closed at Rs 166.65, up Rs 2.00, or 1.21 percent. The 52-week high of the share was Rs 216.80 and the 52-week low was Rs 138.00.
The company's trailing 12-month (TTM) EPS was at Rs 14.76 per share as per the quarter ended June 2013. The stock's price-to-earnings (P/E) ratio was 11.29. The latest book value of the company is Rs 89.75 per share. At current value, the price-to-book value of the company was 1.86.
Anda sedang membaca artikel tentang
Unichem gets USFDA nod for generic hypertension tablets
Dengan url
http://kebugaranhidup.blogspot.com/2013/10/unichem-gets-usfda-nod-for-generic.html
Anda boleh menyebar luaskannya atau mengcopy paste-nya
Unichem gets USFDA nod for generic hypertension tablets
namun jangan lupa untuk meletakkan link
Unichem gets USFDA nod for generic hypertension tablets
sebagai sumbernya
0 komentar:
Posting Komentar